Researchers from the UT Southwestern Medical Center, USA, have announced successful results of a clinical trial for a commonly prescribed weight-loss drug called liraglutide, which, when combined with lifestyle interventions, significantly lowered visceral fat and ectopic fat, risky to heart health. The study, published in ‘The Lancet Diabetes & Endocrinology’, notes that by using the latest imaging technology to evaluate different fat components in the body, the researchers found that there was a significant decrease in visceral fat in patients without diabetes but who were overweight or had obesity. Excess visceral fat and ectopic lead to type 2 diabetes and cardiovascular disease. These results showed the potential of liraglutide treatment for significantly lowering the risk of chronic disease in this population.
Comments are closed.